Khoroshko N D, Turkina A G, Zhuravlev V S, Sokolova M A, Mikhaĭlova I N, Zakharova A V, Domracheva E V, Semenova E A
Ter Arkh. 1996;68(7):22-7.
The aim of this paper was to show the validity of programmed treatment of chronic myeloid leukemia (CML) patients regarding the risk group. In a group of low CML risk monochemotherapy (myelosan or hydroxyurea) was applied. In a group of moderate or high CML risk cytostatic therapy was performed in two variants: as monotherapy and polychemotherapy. Of 112 patients with CML, 50 received cytostatics plus long-term course of interferon-alpha. The combined treatment was well tolerated.
本文旨在展示针对慢性粒细胞白血病（CML）患者风险组进行程序化治疗的有效性。在低CML风险组中应用单一化疗（美法仑或羟基脲）。在中高CML风险组中，进行了两种变体的细胞抑制疗法：单一疗法和联合化疗。在112例CML患者中，50例接受了细胞抑制剂加α干扰素长期疗程的治疗。联合治疗耐受性良好。
